PureCycle Technologies vs Radiopharm Theranostics
PCT and RADX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PCT and RADX compare
PureCycle Technologies grew revenue faster over the last twelve months (142% versus −23.8% for Radiopharm Theranostics).
Radiopharm Theranostics scores higher on the StockData Score (6 against 3 for PureCycle Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PCT | RADX |
|---|---|---|
| Size and price | ||
| Market cap | $343M | – |
| Share price | $1.71 | $0.760 |
| Change, 1 year | −82.2% | −83.8% |
| Change, 5 years | −86.4% | – |
| Beta (5Y) | 1.82 | 1.05 |
| Employees | 174 | 2 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 0 | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 25.0× | – |
| P/B | 18.5× | – |
| FCF yield | −61.0% | – |
| Fair value | $0.163 | – |
| Margin of safety | −943% | – |
| Growth | ||
| Revenue growth (TTM) | 142% (better) | −23.8% |
| Profitability | ||
| Gross margin | – | 9.5% |
| Operating margin | −1314% (better) | −2052% |
| Net margin | −1371% | – |
| FCF margin | −1528% | – |
| Return on equity | −433% | – |
| Financial health | ||
| Interest coverage | −2.9× (better) | −505.2× |
| Current ratio | 1.60 (better) | 1.16 |
| Altman Z-score | −1.61 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Buyback yield | −46.7% | – |
| Shareholder yield | −46.7% | – |
| Ownership | ||
| Held by institutions | 90.6% | 1.4% |
| Held by insiders | 25.3% | 27.5% |
| Insider net buying, 12 months | $98.8K | – |
| Superinvestors holding | 1 | – |
Go deeper
- PCT stock overview
- PCT income statement
- PCT valuation and score
- RADX stock overview
- RADX income statement
- RADX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.